A non-replicating form of pseudotyped influenza virus, inactivated by suppression of the hemagglutinin signal sequence (S-FLU), can act as a broadly protective vaccine. We show that vaccination in the lung induced a strong local CD8 T cell response and protected against heterosubtypic X31 (H3N2) virus and highly virulent PR8 (H1N1), but not influenza B virus. Lung vaccination also induced a strong neutralising antibody response to the encoded neuraminidase. If given at higher dose in the periphery, H7 S-FLU induced a specific neutralising antibody response to H7 hemagglutinin coating the particle. Polyvalent vaccination with mixed H7 S-FLU induced a broadly neutralising antibody response to all four H7 strains. S-FLU is a versatile vaccine candidate that could be rapidly mobilized ahead of a new pandemic threat.
Introduction
Influenza virus causes annual widespread respiratory tract infections resulting in mortality and morbidity in the human population. They can be divided into subtypes and genetic groups according to the hemagglutinin (HA) and neuraminidase (NA)
glycoproteins on their surface [1] . Influenza can generate novel virus variants by genetic reassortment during co-infection with two or more strains, and these can spread rapidly through an unexposed human population to cause pandemics. Recent zoonoses of novel avian influenza viruses, such as H7N7 and H9N2, were localized and caused mild disease [2, 3] . In contrast a novel virulent strain of influenza H7N9
(group 2), not previously isolated in humans, appeared in China from March to May 2013 [4] . Since then there have been 1564 confirmed human infections with influenza H7N9 with at least 612 deaths including an unexpected increase in cases during the 2016/7 influenza season (WHO Risk Assessment 27 September 2017). To date, this virus has been weakly transmissible between humans, but it is concerning that it may need to make only a small number of amino acid substitutions in HA to enable human-to-human transmission [5] , and humans may not have any neutralising antibody. By contrast, during the 2009 H1N1 pandemic it was seen that older people had some protection from infection through cross-reactive antibody induced by earlier H1N1 virus infections [6] [7] [8] . New pandemics can originate from either group 1 or 2 influenza A viruses, so cross protection between genetic groups has recently been defined as a major goal for developing broadly protective influenza vaccines [9] .
Recovery from influenza infection can provide immunity that is cross protective between A viruses in the absence of detectable neutralising antibodies. This was first noticed in 1933 through comparison of infections with swine and human influenza (distantly related H1N1 viruses) in ferrets [10] . It was named "partial specific heterotypic immunity" by Schulman and Kilbourne [11] in 1965, who observed partial protection against an H2N2 virus after recovery from an H1N1 infection in mice. It has been demonstrated in several species including mice, ferrets, guinea pigs, poultry, swine, and non-human primates (reviewed in [12, 13] ), and is associated with reduced virus replication and pathology in the lung, and reduced transmission [14, 15] . Optimal induction of heterotypic immunity requires infection of the lung or total respiratory tract as opposed to infection at a peripheral site, including the nose [16] [17] [18] [19] [20] [21] .
In mice the cross protective effect of prior influenza infection is associated with a cross-reactive Cytotoxic T Lymphocyte (CTL) response, and can be transferred with specific class I restricted CD8 CTLs [22] [23] [24] [25] [26] . Both murine and human CD8 T cells recognize peptides derived from conserved virus proteins processed in the cytosol of infected cells [27] [28] [29] [30] . While cell depletion and gene knockout experiments confirm a central role for T cells, there is evidence for additional contributions from B cells and innate immune cells in heterotypic immunity [31] [32] [33] .
Heterotypic protection has been more difficult to demonstrate in humans (reviewed in [12, 13] ), and may be limited in duration [34] . However, two recent observational studies correlated milder symptoms and reduced virus shedding with strong CD8 T cell memory during the recent H1N1 pandemic [35, 36] . Studies have also demonstrated cross-reactive T cells that recognize conserved components of the H7N9 and H5N1 viruses in individuals exposed only to seasonal influenza [37, 38] , and a further study correlated high levels of cross-reactive CD8 T cells with milder disease in humans hospitalized with H7N9 infection [39] . These observational studies on natural influenza infections support evidence for T cell associated protection of humans from experimental influenza [40, 41] .
The sum of evidence suggests that the protective mechanism of heterotypic immunity to influenza is multifactorial with CD8 T cells playing a central role. For this reason it seems logical that vaccines designed to induce it should be as closely related to live influenza as possible. We previously demonstrated that a novel replication deficient influenza virus vaccine, based on inactivation of the HA signal sequence ( [42] hence "S-FLU"), coated with H1 hemagglutinins can induce cross protective immunity against PR8 (H1N1, group 1) and X31 (H3N2, group 2) viruses which have divergent surface glycoproteins but the same internal genes as S-FLU [43] .
We have shown that in ferrets immunization with H1N1 or H5N1 S-FLU (group 1)
significantly reduced replication of H1N1, H6N1, H5N1 (group 1) and H7N9 (group 2) wild-type viruses in the lung [44] . In pigs, immunization with H1N1 or H5N1 S-FLU reduced virus titres in nasal swabs and lungs following challenge with a swine H1N1pdm09 isolate and [45] . S-FLU can infect cells for one round only, but this is sufficient to express all the conserved virus proteins in the cytosol for induction of a vigorous local CD8 T cell response. Other similar non-replicating influenza constructs were also able to protect animals vaccinated in the lung (reviewed in [46] ).
S-FLU viruses are similar to Live Attenuated Influenza Virus (LAIV) [47, 48] in terms of being able to stimulate strong T cell mucosal immunity and heterotypic protection in mice and ferrets [43, 46] , but have two major advantages over the licensed form of LAIV. S-FLU is unable to replicate so vaccinees should not shed virus [49] , and in addition S-FLU cannot donate a pandemic HA sequence to seasonal influenza by reassortment because it is coated in the HA glycoprotein, but does not contain the pandemic vRNA encoding HA [43] . We show here that vaccination in the lung with a novel form of S-FLU that is pseudotyped (coated) with H7 hemagglutinin from the A/Anhui/1/2013 H7N9 influenza virus protects mice against challenge with viruses of different HA subtype, highly lethal PR8 (H1N1 Cambridge strain) and X31
(H3N2), but carrying the same conserved internal genes as the S-FLU constructs.
Protection after intranasal (i.n.) administration is associated with a strong local crossreactive CTL response in the lung.
Lung immunization with protective doses of S-FLU is not able to generate a reliable neutralising antibody response to the HA glycoprotein coating the pseudotyped particle [43] , probably because the S-FLU infected cells cannot synthesize HA.
However, we now demonstrate that the priming dose of S-FLU in the lung does induce a strain specific neutralising antibody response targeting the encoded NA, which unlike the HA is synthesized by infected cells. Further, H7-S-FLU given in a larger dose in the periphery (intraperitoneally (i.p.)) can generate a strong neutralising antibody response both to the H7 HA coating the particle, in addition to the encoded N1 NA. Administration of a mixture of S-FLU, coated in diverse H7 HAs, induced a broadly neutralising antibody response to the four viruses in the mix (including Eurasian and North American strains), as well as cross-reactive T cells in the spleen.
S-FLU, because it closely mimics natural influenza infection, but can neither replicate nor reassort an HA vRNA, may function as a versatile pre-pandemic vaccine for the induction of cross protective T cells to the conserved internal proteins and neutralising antibodies to the glycoproteins coating the virus.
Materials and Methods
Media, Reagents and Tissue Culture: Virus Growth Media (VGM) was DMEM with 0.1% bovine albumin (Sigma A0336), 10 mM HEPES, 2 mM glutamine, 100 U/mL penicillin and 100 µg/mL streptomycin (all from Sigma, Poole UK). D10 was DMEM with 10% v/v foetal calf serum (Sigma) plus glutamine and antibiotics as above. R10 was RPMI (Sigma) with 10% serum, glutamine and antibiotics. MDCK-SIAT1 cells [50] were obtained from the European Collection of Cell Cultures (ECACC) distributed by Sigma.
Influenza Viruses: Plasmids carrying the genes of the Cambridge strain of A/Puerto Rico/8/34 were used to generate PR8 virus [43] . A reassortant containing the HA and NA from A/Aichi/2/68 (H3N2) and internal genes of PR8, X31 [51] , was a gift from J McCauley (Crick Worldwide Influenza Centre, The Francis Crick Institute, London).
Viruses were produced as culture supernatants from MDCK-SIAT1 cells [50] using standard methods and were stored at -80 o C after centrifugation.
Antibodies to Influenza: Human monoclonal antibodies (mAbs): Anti-NP 2-8C has been described [43] . 9B-26 specific to H7 HA from A/Anhui/1/2013, was isolated from a plasmablast FACS sorted from a peripheral blood sample provided by a donor post recovery from infection using standard methods [8, 52] [55] .
Production of S-FLU:
The development of S-FLU has been described in detail [43] .
The S-eGFP vRNA that replaces the HA vRNA was derived by suppression of the 
Enzyme Linked Lectin Assay (ELLA) for Neuraminidase Inhibiting Antibody:
The assay was performed as described [60, 61] whole respiratory tract to the inoculum [63] , at day 0 and day 14-16. We refer to this as "lung immunization". Animals were routinely monitored at least twice weekly by observation and weighing. Challenge with PR8 or X31 virus took place at least a further 4 weeks later and was done using intranasal challenge as above with virus diluted in VGM. Weight loss and gain was monitored daily and morbid animals were humanely killed by cervical dislocation or inhalation of carbon dioxide. Morbidity was judged using 20% weight loss as an end point or a clinical scoring system [64] .
Conditional survival was the percentage of animals not reaching 20% weight loss or a threshold clinical score or a combination of both. During the experiments one vaccinated animal unexpectedly died after challenge having lost 5% body weight, and one animal mock vaccinated with Viral Growth medium died before challenge.
Virus Isolation from Lungs:
Virus concentrations from infected lungs were measured as described previously [43] . Briefly: lungs were removed from freshly killed mice, weighed and snap frozen in liquid nitrogen. Thawed lungs were homogenized using a QiaShredder (Qiagen, UK) and centrifuged at 12000 rpm for 1 min. Supernatants were recovered and virus titre measured using TCID 50 as described above with the additional step of filtration of the diluted lung through a 0.22 µm spin filter (Millipore, UK) prior to plating.
Antibody and T cell assays:
Samples of mouse sera and immune organs were treated and analyzed as previously described [43] and were assayed for MN and ELISA activities using similar techniques apart from the fact that H7 S-FLU was used in MN assays in addition to PR8 and X31. ELISA assays used purified soluble H7
glycoprotein produced in stably transduced 293T cells as described [43] : plates were coated with a 20 µg/mL solution (in PBS) for 2 hours and blocked overnight with 5% milk. ELISPOT assays were performed as previously described [43] 
RESULTS

Growth Properties of H7 S-FLU
Initially we assessed whether H7 S-FLU infected susceptible cells and expressed NP protein at a similar level to PR8 virus. Viruses were titrated in 96 well plates and then MDCK-SIAT1 cells were placed into each well and incubated overnight. Following labeling with anti-NP mAb (2-8C) and secondary anti-human HRP, we showed that there was a similar level of NP expression for both H7 S-FLU and PR8 virus ( Figure   1A ). We then added titrated viruses to MDCK-SIAT1 monolayers in the presence of cells that were present in the blood after one dose, increased after a second dose, and remained in circulation for at least 63 days (Figure 2A ). On day 64 we killed groups of four mice and determined the percentages of tetramer positive cells that persisted in lung and spleen ( Figure 2B ). At day 64 there was a population of ~6% CD8+ tetramer binding cells present in the lungs of immunized animals that was not present in VGM primed mice ( Figure 2C ).
Antibody to HA:
We have previously shown that after lung vaccination with doses of < 10 6 TCID 50 a weak antibody response to the HA pseudotyping (coating) the S-FLU particle is generated that can be detected by ELISA but rarely in the MN assay [43, 46] . This was the case at day 64, 40 days after the second dose of 16 HAU (7x10 Additional specificity controls were (i) the murine mAb NC2-1C1 [53] that inhibited the N1 from PR8 but not N1pdm09 (Column 11), ii) the murine mAb CD6 [54] that inhibited viruses carrying N1pdm09 NA with an IC 50 of 49 ng/mL, similar to the reported value of 64 ng/mL [54] , but was non-reactive with the N1 (PR8), ( Figure 5 , column 12).
Cross protection following vaccination with H7 S-FLU.
To assess if H7 S-FLU vaccination gave cross protection, groups of mice were Figure 6D ). This level of protection was less than that seen with homotypic challenge after H1 (PR8) S-FLU priming and wild type PR8 challenge, where complete protection without weight loss was observed [43] . In addition a single dose of 7.35x10 5 or 7.35x10 4 TCID 50 H7 S-FLU was able to protect mice against challenge with 0.32 HAU (10 4 TCID 50 ) PR8 ( Figure 6E ).
Titration of H7 S-FLU and histology during challenge.
Further to showing that a dose of 16 HAU (7.35x10 5 TCID 50 ) of H7 S-FLU was protective, we determined at which concentration two doses of the H7 S-FLU vaccine failed to protect. Animals were dosed with ten-fold dilutions of H7 S-FLU and doses as low as ~700 TCID 50 were protective while a dose of ~70 TCID 50 was not ( Figure   7A ). However, mice immunized twice with 735 TCID 50 did have more noticeable weight loss upon challenge than mice immunized with higher doses ( Figure 7A ). We also measured virus titre in the lungs at day 3 post-challenge for some of these groups: mice primed with two doses of 7x10 5 To establish whether neutralising antibody and T cells were generated to the priming and challenge doses given i.n, we performed MN and ELISA assays on serum samples from mice collected at least 30 days post-challenge. A significant response to H7 HA was detected by ELISA (not shown), but the antibodies were not neutralising (Figure 3) , which is consistent with responses to the H1 S-FLU described previously [43] . By contrast there was a strong response to the challenge virus in the serum (Figure 8 ).
The neutralising anti-HA antibody response to PR8 challenge virus was dependent on both the priming dose of H7 S-FLU and the challenge dose of PR8. Figure 8A shows that the MN titre in the serum to the PR8 challenge virus was inversely proportional to the priming dose of H7 S-FLU ( Figure 8B ). In addition, mice challenged with 32 HAU of PR8 had higher MN titres to PR8 than mice challenged with 0.32 HAU PR8
( Figure 8C ).
Discussion
We as also shown in Figure 3 for the equivalent S-FLU. If S-FLU were to be given to humans in a similar dosage to LAIV this represents 1-10 doses/ml for human and 1-10 x 10 4 murine doses/mL. These results confirm and extend our earlier experiments with S-FLU coated in H1 HAs [43] , and the work on related single-cycle infectious influenza A viruses (reviewed in [46] ).
The protective effect of the H7 S-FLU is specific to influenza A (not B), as found in the classic description of "partial specific heterotypic immunity" [11] , which was transferrable with cross-reactive class I restricted CTL [24] [25] [26] . Evidence has accumulated for a cross protective effect associated with the Class I restricted T cell response in humans [35, 36] , including recent evidence for a correlation between a strong cross-reactive CTL response and milder outcome after H7N9 infection in humans [39] . We also showed that an H5 S-FLU with internal genes from A/PR/8/34
can prevent replication of wild type H7N9 (A/Anhui/1/2013) in mice and ferrets [44] .
This suggests that S-FLU and other single-cycle infectious influenza A viruses [46] could be useful in the stimulation of cross subtype immunity for protection against future pandemic influenza A viruses.
Antibodies to NA can have a significant protective effect against influenza in animal models of infection [66, 67] , and evidence from vaccine trials strongly suggests this is true for human infections [68] . The inhibition of NA by antibody does not usually block virus entry (so would not be detected in the neutralisation assay we use), but prevents virus release, and reduces plaque size in vitro [54, 66, 69] . Recent evidence shows that an engineered influenza can use NA as a receptor-binder, making the sialic acid binding function of HA redundant, and reserving HA for its fusion function alone [70, 71] . If such a virus evolved naturally, vaccines that stimulate a strong neutralising antibody to NA would be essential.
We have demonstrated that cells infected with S-FLU express the PR8 NA in the absence of HA at the cell surface at similar levels to cells infected with wt A/PR/8/34
( Figure 1 ). Therefore S-FLU might be expected to induce an antibody response to NA, and we have shown this conclusively, both after administration to the lung at low dose, and an enhanced response after larger doses i.p. (Figure 5 ). The response to NA is strain specific, as the antibody induced to the N1 NA from PR8 does not cross- After i.n. administration of a low dose (<10 6 TCID 50 ) of S-FLU an antibody response to the HA coating S-FLU can be detected by ELISA [43] , but it is predominantly nonneutralising ( Figure 3 ). This is probably due to the lack of synthesis of new HA by S-FLU infected cells. However, H7 S-FLU given at ten-fold higher dose, in the peritoneal space, generates a robust neutralising antibody titre to A/Anhui/1/2013 HA, in addition to a T cell response to a conserved nucleoprotein epitope detected in the spleen (Figures 3, 4) . The dose required to induce this neutralising antibody response, while ten-fold higher than that given to the lung, is still a low dose in absolute terms:
160 HAU (~7 x10 6 DNA vaccine [75] , and a tetravalent VLP vaccine [76] . These new results with an H7 from a group 2 virus, that is viewed as a pandemic threat, extend our earlier work with S-FLU coated in H1 HAs from group 1 viruses, A/PR/8/34 and the H1N1pdm09 virus A/England/195/2009, which also induced strain specific neutralising antibodies after i.p. inoculation [43] . This suggests that S-FLU particles are strongly immunogenic for B cells when given in the periphery, as has been seen with wt influenza [77] .
In vaccinated mice we found a strong neutralising antibody response to the challenge virus at one month post infection, in situations where replication of the challenge virus was clearly suppressed at day 3 post-challenge (Figures 7,8 ). The titre of neutralising antibody generated post-challenge was inversely proportional to the dose of the priming vaccine S-FLU virus vaccine, as was the degree of replication of the challenge virus detected in the lung. This suggests that the level of neutralising antibody generated after challenge is related to the degree of replication that occurs, and the higher dose of H7 S-FLU gives a stronger immune response that prevents challenge virus replication and thus dampens the antibody response. The animals which received lower doses of vaccine had detectable virus replication at day 3, lost more weight, and generated the highest neutralising antibody titres to the challenge virus.
The heterotypic protection provided by S-FLU is thus not sterilizing, as indicated in the first description of this phenomenon [11] . The strong neutralising response to the challenge virus may be an additional benefit of S-FLU, as this would provide longterm antibody-based protection, and also strengthen and prolong the T cell response.
Together these results show that S-FLU is a flexible influenza vaccine candidate as it can be produced with various surface HAs and NAs, it can stimulate both local cross protective T cell responses, and systemic neutralising antibodies to HA and NA, depending on how it is administered. In principle, it could be given both to the lung to induce cross protective T cells, and as a mix of strains in the periphery to induce both a broad neutralising antibody response and sustain the heterosubtypic protection provided by the T cell response [21] . 
